Finance

Mga Listahan
WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
฿5.20
0.00%
(0.00) 1D
Okt 15, 4:40:00 PM GMT+7  ·   THB
Lahat ng simbolo
SimboloPresyoPalitan% ng Pagbabago
Bumubuo ng mga nangungunang insight para sa WUXI06...
Buksan
฿5.25
Mataas
฿5.35
Mababa
฿5.05
Mkt. cap
198.43B
Avg. na dami
93.60K
Dami
288.50K
Mataas nang 52-wk
฿6.25
Mababa nang 52-wk
฿3.02
Mga natitirang share
4.12B
Bilang ng mga empleyado
15K
Buksan
฿5.25
Mataas
฿5.35
Mababa
฿5.05
Mkt. cap
198.43B
Avg. na dami
93.60K
Dami
288.50K
Mataas nang 52-wk
฿6.25
Mababa nang 52-wk
฿3.02
Mga natitirang share
4.12B
Bilang ng mga empleyado
15K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Tungkol sa Wuxi Biologics (Cayman) Inc. KKPS DR
CEOZhisheng Chen
Mga Empleyado14.7K
Itinatag2010
Headquarters-
Sektor-
Mga nakaraang ulatLahat ng value sa CNY
Loading Previous Earnings...
Kita
Net na kita
Lahat ng value sa CNY
Set 2025
Dis 2025
Mar 2026
Hun 2026
Kita
5.92B
5.92B
5.89B
5.89B
Gastusin sa mga naibentang produkto
3.04B
3.04B
3.17B
3.17B
Halaga ng kita
3.04B
3.04B
3.17B
3.17B
Mga gastos sa pananaliksik at pag-develop
254.93M
254.93M
215.11M
215.11M
Kabuuang gastos sa pananaliksik at pag-develop
-
-
-
-
Mga gastos sa pagbebenta, pangkalahatan, at admin
631.03M
631.03M
591.61M
591.61M
Gastos sa pagpapatakbo
921.71M
921.71M
860.09M
860.09M
Kabuuang gastos sa pagpapatakbo
3.96B
3.96B
4.03B
4.03B
Kita sa pagpapatakbo
1.96B
1.96B
1.86B
1.86B
Iba pang hindi kita sa pagpapatakbo
33.58M
33.58M
42.20M
42.20M
EBT na may mga hindi karaniwang item
1.96B
1.96B
1.71B
1.71B
EBT na hindi kasama ang mga hindi karaniwang item
1.94B
1.94B
1.70B
1.70B
Gastos sa buwis sa kita
476.10M
476.10M
251.54M
251.54M
Epektibong rate ng buwis
24.24%
24.24%
14.71%
14.71%
Iba pang gastos sa pagpapatakbo
-
-
-
-
Net na kita
1.28B
1.28B
1.22B
1.22B
Margin ng kabuuang kita
21.70%
21.70%
20.70%
20.70%
Kita bawat share
-
-
-
-
Kita sa interes at investment
115.29M
115.29M
106.38M
106.38M
Gastos sa interes
-29.76M
-29.76M
-22.28M
-22.28M
Mga net na gastos sa interes
85.53M
85.53M
84.10M
84.10M
Mga singil sa depreciation at amortization
-
-
-
-
EBITDA
2.24B
2.24B
2.27B
2.27B
Kita o pagkalugi mula sa pagbebenta ng mga asset
317.34M
317.34M
-
-
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa
Mga app ng Google